Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Early surgery offers long-term survival, lowers risk of heart failure in mitral valve regurgitation patients

Early surgery offers long-term survival, lowers risk of heart failure in mitral valve regurgitation patients

AliveCor Heart Monitor for iPhone can detect heart rhythm problems, prevent strokes

AliveCor Heart Monitor for iPhone can detect heart rhythm problems, prevent strokes

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

NPS MedicineWise programs improve prescribing, cardiovascular management in primary care

NPS MedicineWise programs improve prescribing, cardiovascular management in primary care

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

August edition of NPS RADAR includes reviews for new medicines listed on PBS

August edition of NPS RADAR includes reviews for new medicines listed on PBS

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

Study documents reversal of established medical practices in last decade

Study documents reversal of established medical practices in last decade

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

LARIAT procedure prevents stroke in patients who are unable to tolerate blood thinners

LARIAT procedure prevents stroke in patients who are unable to tolerate blood thinners

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Innovative procedure for atrial fibrillation reduces risk for stroke

Innovative procedure for atrial fibrillation reduces risk for stroke

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen receives complete response letter from FDA for XARELTO sNDA

Study reports catheter ablation is more effective in preventing AFrecurrence

Study reports catheter ablation is more effective in preventing AFrecurrence

European study to evaluate CardioFocus' HeartLight Endoscopic Ablation System in AF patients

European study to evaluate CardioFocus' HeartLight Endoscopic Ablation System in AF patients

Study finds U-shaped association between consumption of fish and risk of developing AF

Study finds U-shaped association between consumption of fish and risk of developing AF

Study recommends depression screening In AF clinics

Study recommends depression screening In AF clinics

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.